Clinical Trial Search

Primary: Percentage of Patients With an Incidence of Adverse Event (AE) Associated to Potential Liver Damage During the Clinical Evaluation of Patients — 0.0 Percentage of Patients

Primary: Number of Participants Who Had Experienced a New Health Problem or the Worsening of an Existing Health Condition That Resulted in a Medical Consultation — 153 participants

Primary: Number of Participants With Treatment-Related Adverse Events of Etanercept — 22 participants

Primary: Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane — 126; 324; 372; 68 participants

Primary: Twenty One Pre-specified Outcomes of Interest as Obtained From International Coding of Diseases (ICD-9) Codes Captured After Adacel Vaccination in Clinical Database — 0…

Primary: Number of Participants With Acute Scaffold Thrombosis (ST) — 0; 0; 0 participants

Primary: Total Number of Patients With Adverse Events — 27.8 Percentage of Patients

Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 15; 59; 2; 7 participants

Primary: Number of Participants With at Least One Adverse Events of Specific Interest (AESI) From Month 0 to Month 79 — 12; 11; 16 Participants

Primary: Number of Patient Encounters That Report a New or Worsening Symptom — 8 Participants

Primary: Health Services Utilization 3 Months Following Hospital Discharge — 3.33; 3.40 Health Services Utilizations — p=.87

Primary: Number of Participants Experiencing AEs or ADRs — 184; 59 Participants

Primary: Percentage of Participants With Serious Adverse Events (SAEs) and Serious Adverse Drug Reactions (SADRs) — 0.15; 0.00 percentage of participants

Primary: Percentage of Participants With Adverse Drug Reactions (ADRs) — 23.53 percentage of participants

Primary: Incidence of Acute Myocardial Infarction (AMI) — 3.3; 5.2 Events per 1000 person years — p=.68

Primary: Number of Participants Who Had Experienced a New Health Problem or the Worsening of an Existing Health Condition That Resulted in a Medical Consultation. — 234…

Primary: CSAE-score Rate(Clinical Significant Adverse Events Score Rate) — 0.112; 0.128; 0.075 score/month — p=0.0028

Primary: Usability of the SAM App — 1.14; 1.32; 1.35; 1.81 score on a scale

Primary: Number of Participants With Adverse Drug Reactions — 1858; 518 Participants

Primary: Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection, Serious Arrhythmia and/or Death — 303; 349 participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 19; 49; 8; 29 participants

Primary: Drug-related Adverse Events Consisting of Epoetin Alfa-induced Immunogenicity and Resulting Clinical Effects — 7; 0.18 percentage of participants

Primary: Number of Participants Reporting a Solicited Local or Systemic Reaction Post-Vaccination With Either REPEVAX® or COVAXIS® Vaccine — 89; 87; 85; 87 Participants

Primary: Number of Participants Experiencing Adverse Events (AEs) — 324 participants

Primary: Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group — 0.00; 0.00; 0.00; 10.10 Percentage of…

Primary: Percentage of Participants With Serious Adverse Events (SAEs) — 1.18 percentage of participants

Primary: Safety Assessment Including Treatment-related Adverse Events (Number of Participants Who Experienced at Least One Adverse Event (AE) or One Serious Adverse Event (SAE))…

Primary: Number of Subjects Reporting European Medical Agency (EMA) Defined Adverse Events of Interest (AEIs) (Any) & Onset Dates of AEIs Using a Card Based-adverse Drug Reaction…

Primary: Prevalence of Respiratory Tract-Related Adverse Events of Interest — 52; 51; 16; 14 percentage of participants